Traws Pharma (TRAW)10% owner bought ~$998K

~$998K

Approx. value · 598K sh @ $1.67

1.2M

Holds after · shares reported

Traded

Apr 16, 2026

Filed

Apr 29, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 15, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
2. Apr 15, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
3. Apr 16, 2026 · this disclosureInsider · First insider buy since Jan 202210% owner purchased ~$998K of TRAW shares in the open market

What came next

1. May 15, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
2. Jul 8, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“As described in Item 5.07 below, on July 8, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Traws Pharma, Inc. (the “Company”), the Company’s stockholders approved an amendment to the Company’s 2021 Incentive Compensation Plan (as so amended, the “Plan”), to increase the number of shares of common stock available for issuance by 2,000,000 and make certain other administrative changes (the…”
3. Jul 29, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On July 29, 2026, Traws Pharma, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for at least 30 consecutive business days, the Company is not currently in compliance with the minimum bid price requirement for…”
4. Aug 14, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Traws Pharma

OQRO holds no insider, Congress, fund or contract record for Traws Pharma dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TRAW page.

Other recent filings by ORBIMED ADVISORS LLC, 10% owner

• SEC Form 4 at Pmv Pharmaceuticals (PMVP)Sep 12, 2025
• SEC Form 4 at Shattuck Labs (STTK)Sep 3, 2025
• SEC Form 4 at Shattuck Labs (STTK)Sep 3, 2025
• SEC Form 4 at Corvus Pharmaceuticals (CRVS)Jul 2, 2025
• SEC Form 4 at Passage Bio (PASG)Jun 26, 2025

The full history of ORBIMED ADVISORS LLC, 10% owner is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans